LM N°1 / 2023. Good practice in the preparation of human blood-derived biological products such as Platelet Rich Plasma (PRP). Antoine TURZI, President of REGENLAB
Good practice in the preparation of human blood-derived biological products such as Platelet Rich Plasma (PRP) Antoine TURZI. President of REGENLAB New innovative therapies characterized as autologous (organic substance whose donor and recipient are the same individual) are coming onto the market. Their preparation depends on the use of special devices [...].
LM N°1 / 2023. NEWS. MODERN CELL THERAPY AND TISSUE ENGINEERING TURN 20! "WELCOME TO REGENERATIVE MEDICINE". Antoine TURZI, CEO of REGENLAB
Editorial Welcome to regenerative medicine. Cell therapies and tissue engineering are 20 years old! Antoine Turzi CEO of REGENLAB I/ Welcome to the world of regenerative medicine research Some 50 years ago, Prof. Joseph Vacanti (John Homans Professor of Surgery, Massachusetts General Hospital, USA) taught the world [...].
LM N° 3/ 2022. Another look. Swiss medical devices for autologous regenerative medicine. Farid Gomri, Solange Vischer, Antoine Turzi, Sarah Berndt
Another look Swiss medical devices for autologous regenerative medicine. Antoine Turzi CEO at Regen Lab SA (Switzerland) Sarah Berndt. PhD in Biomedical and Pharmaceutical Sciences- Head of Cell Therapy Research at Regen Lab SA Solange Vischer. Senior scientific advisor at Regen Lab AG Farid Gomri. General Manager Regen Lab Africa and Business & [...]
LM N° 3/ 2022. Another look. Good practice in the preparation of human blood-derived biological products, such as Platelet Rich Plasma (PRP). Daphne V. Dierman, PhD Pharmacist, Sanaa Benkirane, PhD Pharmacist, Farid Gomri, Msc, Biologist, Antoine Turzi, CEO RegenLab.
Another look Good preparation practices for human blood-derived biological products: Platelet Rich Plasma (PRP) Daphne V. Dierman, PhD Pharmacist, Sanaa Benkirane, PhD Pharmacist, Farid Gomri, Msc, Biologist, Antoine Turzi, CEO RegenLab. Introduction New innovative therapies characterized as autologous (organic substance whose donor and recipient are the same person) are being developed.